KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Current Deferred Revenue (2016 - 2025)

Pacific Biosciences Of California has reported Current Deferred Revenue over the past 16 years, most recently at $15.9 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $15.9 million for Q4 2025, up 14.95% from a year ago — trailing twelve months through Dec 2025 was $15.9 million (up 14.95% YoY), and the annual figure for FY2025 was $15.9 million, up 14.95%.
  • Current Deferred Revenue for Q4 2025 was $15.9 million at Pacific Biosciences Of California, down from $16.0 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for PACB hit a ceiling of $32.1 million in Q2 2022 and a floor of $9.5 million in Q2 2021.
  • Median Current Deferred Revenue over the past 5 years was $16.3 million (2023), compared with a mean of $19.3 million.
  • Biggest five-year swings in Current Deferred Revenue: surged 236.52% in 2022 and later tumbled 46.42% in 2023.
  • Pacific Biosciences Of California's Current Deferred Revenue stood at $11.0 million in 2021, then soared by 177.84% to $30.5 million in 2022, then tumbled by 46.42% to $16.3 million in 2023, then fell by 15.16% to $13.9 million in 2024, then grew by 14.95% to $15.9 million in 2025.
  • The last three reported values for Current Deferred Revenue were $15.9 million (Q4 2025), $16.0 million (Q3 2025), and $14.9 million (Q2 2025) per Business Quant data.